The clinical-stage biotech using the body's own metabolites as bait to find drug pockets that everyone else calls undruggable.
Most drug discovery begins with a difficult protein and a long, expensive hunt for somewhere - anywhere - a molecule might grip it. Atavistik Bio, a biotechnology company at 75 Sidney Street in Cambridge, reversed the question. Instead of searching a protein for a foothold, it asks which small molecules the human body already uses to control that protein, and lets those metabolites reveal the pocket.
That inversion is the whole company. Metabolites - the tiny chemicals of everyday metabolism - are natural regulators of protein and RNA function. Atavistik uses them as bait to surface otherwise hidden allosteric binding sites: places on a protein, away from the obvious active site, where a drug can quietly change behavior. Many proteins tied to disease have no classic pocket at all. Allostery is how you reach them.
The approach has a name, AMPS - Atavistik Metabolite-Protein Screening - and a paper trail. Its foundational technique was published in Science by co-founder Jared Rutter, then industrialized in-house and paired with an AI-enabled design engine. Since 2021 the company has raised roughly $340 million and pushed two programs toward the clinic: an oral AKT1-selective inhibitor for a rare bleeding disorder, and a JAK2 mutant-selective inhibitor for blood cancers.
What follows is a look at what Atavistik Bio does, who it serves, and where a 37-person team fits inside one of biotech's hardest problems - drugging the previously undruggable.
"Metabolites are natural regulators of protein and RNA function. AMPS uses them as bait to reveal otherwise hidden allosteric pockets."
The engine is deceptively simple to describe and hard to build: use nature's own regulators to find a site, confirm it, design a molecule, and prove it in patients.
AMPS systematically tests metabolites against target proteins to see which ones bind - and where.
Binding metabolites expose hidden allosteric pockets, including cryptic sites invisible to standard screens.
AI and structure-based design turn those sites into selective small molecules.
Validated candidates move into IND-enabling studies and the clinic.
A large fraction of disease-driving proteins lack a classic active-site pocket, or can't be hit selectively without harming the healthy version. That leaves genetically validated targets sitting untouched. Atavistik's premise: the binding site exists - it's just allosteric and hidden, and a metabolite can point to it.
Rather than blindly screening enormous chemical libraries, Atavistik starts from the metabolites cells already use to regulate a protein. That biological head start narrows the search to real, functional pockets - and pairs it with AI-driven structure-based design instead of leaving it to luck.
Programs like the JAK2 V617F effort aim to inhibit a cancer-driving mutant form while leaving normal JAK2 alone - the kind of precision allostery makes possible.
Because metabolite-protein interactions are everywhere in biology, AMPS is target-class versatile - which is how a single company runs programs across a rare vascular disorder and blood cancers at once.
| Program | Target | Indication | Status |
|---|---|---|---|
| ATV-1601 | AKT1-selective (oral) | Hereditary Hemorrhagic Telangiectasia (HHT) | IND cleared · Fast Track |
| JAK2 program | JAK2 V617F mutant-selective | Myeloproliferative Neoplasms (MPNs) | Toward clinical PoC |
| AKT1 (oncology) | AKT1 E17K allosteric | Advanced solid tumors / breast cancer | Explored |
| AMPS platform | Metabolite-protein screening + AI | Multiple target classes | Core engine |
Status reflects publicly reported milestones through mid-2026; details are approximate and subject to change.
Atavistik builds proprietary allosteric assets on AMPS and funds R&D through equity, aiming for value via clinical proof of concept, partnerships, or products. Pre-commercial and R&D-stage today.
End beneficiaries are patients with HHT, MPNs, and cancer, reached through physicians. Near-term stakeholders are biopharma partners and investors.
It sits among allosteric and precision small-molecule players chasing hard targets - a metabolite/chemoproteomics-flavored take on a crowded, high-stakes field.
Allosteric and hard-target specialists such as Relay Therapeutics, Scorpion Therapeutics, Nurix, and Kymera, plus the broader universe of precision-oncology and rare-disease drug developers. Atavistik's wedge is its metabolite-first discovery engine.
Investors include Nextech Invest, The Column Group, Lux Capital, Regeneron Ventures, and RA Capital Management. Bar widths are illustrative, scaled to round size.
Professor of Biochemistry, University of Utah. Author of the Science paper behind AMPS.
Professor at UT Southwestern; a leading voice on human metabolism.
Leads the science and platform strategy.
Leads company strategy, financing, and clinical progress.
Chairs the board of directors.
Oversees clinical development.
Atavistik emerges in Cambridge to pursue genetically-validated targets in metabolic disease and cancer.
Co-founder Jared Rutter publishes the MIDAS technique underpinning the platform.
An added $40M pushes the lead precision-allosteric oncology program toward the clinic.
Regeneron Ventures joins to fund AKT1 (HHT) and JAK2 V617F (MPNs) toward proof of concept.
FDA IND clearance and Fast Track for HHT; a further ~$40M supports the program.
Sources compiled from company site and public reporting (GlobeNewswire, BioSpace, MedCity News, Crunchbase, PharmExec, FinSMEs). Figures are approximate where noted.